Journal of Isfahan Medical School

Journal of Isfahan Medical School

Treatment of Glucantim™-Resistant Cutaneous Leishmaniasis Using Combination Therapy of Allopurinol and Trichloroacetic Acid (TCA) 50%; Report of Three Cases

Document Type : Case Report

Authors
Giti Sadeghian 1
Fatemeh Sokhanvari 2
1 Dermatologist, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 General Practitioner, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Leishmaniasis is a disease transmitted by insects and in total, 88 countries are involved. If there is no remission with Glucantim as a choice of drug, other treatments such as cryotherapy and thermotherapy methods are used or other drugs such as allopurinol, pentamidine and amphotericin are prescribed in this disease. The use of trichloroacetic acid (TCA) 50% solution is another effective treatment.Case Report: We report three cases (two women and one man) of cutaneous leishmaniasis resistant to Glucantim treated with combination therapy of allopurinol and TCA 50%.Conclusion: According to the results, the use of combination therapy of allopurinol and TCA 50% could be used as one of the alternative treatments in Glucantim™-resistant cutaneous leishmaniasis.
Keywords
Cutaneous leishmaniasis
Glucantim
Allopurinol
Trichloroacetic acid (TCA) 50%
  1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27(5): 305-18.
  2. World Health Organization. Cutaneous leishmaniasis: control in selected countries of the WHO Eastern Mediterranean and African Regions. Report of an interregional network meeting, Casablanca, Morocco, 23–24 June 2014. Geneva, Switzerland: WHO; 2015.
  3. Grogl M, Thomason TN, Franke ED. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 1992; 47(1): 117-26.
  4. Gramiccia M, Gradoni L, Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol 1992; 86(6): 613-20.
  5. Berman JD. Treatment of New World cutaneous and mucosal leishmaniases. Clin Dermatol 1996; 14(5): 519-22.
  6. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 326(11): 741-4.
  7. Saenz RE, Paz HM, Johnson CM, Marr JJ, Nelson DJ, Pattishall KH, et al. Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside. J Infect Dis 1989; 160(1): 153-8.
  8. Marr JJ, Berens RL. Antileishmanial effect of allopurinol. II. Relationship of adenine metabolism in leishmania species to the action of allopurinol. J Infect Dis 1977; 136(6): 724-32.
  9. Martinez S, Gonzalez M, Vernaza ME. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis 1997; 24(2): 165-9.
  10. Nilforoushzadeh MA, Sadeghian G, Jaffary F, Ziaei H, Shirani-Bidabad L, Mahzoni P. Successful treatment of lupoid cutaneous leishmaniasis with Glucantime and topical trichloroacetic acid (a case report). Korean J Parasitol 2008; 46(3): 175-7.
  11. Nilforoushzadeh MA, Jaffary F, Reiszadeh MR. Comparative effect of topical trichloroacetic acid and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Int J Pharmacol 2006; 2(6): 633-6.
  12. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41(8): 521-4.
  13. Momeni AZ, Reiszadae MR, Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate. Int J Dermatol 2002; 41(7): 441-3.
  14. Shamsi Meymandi S, Dabiri S, Bahreini M. Effect of Allopurinol on L. Major Promastigots resistant to Glucantim in vitro. J Kerman Univ Med Sci 2003; 10(3): 158-65. [In Persian].
Journal of Isfahan Medical School
Volume 34, Issue 405 - Serial Number 405
September and October 2017
Pages 1318-1322

  • Receive Date 07 November 2016
  • Accept Date 06 April 2022